Abstract
The knowledge of regulatory affairs is continuously improving in the pharmaceutical industry. The quality, safety and efficacy of the drug are related to various factors. Still, one of the vital system needed for marketing is that company should have a proper regulatory department. Our research process focuses on the regulatory department in the pharmaceutical industry and also the present situation of Nanoparticles across US, EU and India. The Nanotechnology in the Indian pharmaceutical industry is taking an excellent path. Still, when compared to USFDA and EU, there are some steps to be taken for the development of Nanotechnology. This study is mainly focused on Nanoparticles (Liposomes & Niosomes). By comparing the US and EU regulatory markets, we can build a strong regulation in the Indian market on Liposomes and Niosomes. The aim of this study is also focused on present regulations on Liposomes and Niosomes in the three market regions, i.e. in the US, EU and India and present market strategies. By this study, we can gain knowledge on marketing developments of Nanoparticles (Liposomes and Niosomes).
Full text article
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.